'Lesion length' presentation slideshows

Pros and cons of FFR in multivessel disease: from FAME to ACS

Pros and cons of FFR in multivessel disease: from FAME to ACS. Giuseppe Biondi Zoccai University of Modena and Reggio Emilia, Modena, Italy gbiondizoccai@gmail.com. Learning goals. Scope of the problem What are the implications of FAME What about the culprit lesion in ACS

771 views • 37 slides

Gregg W. Stone, MD for the SPIRIT IV Investigators

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease One Year Clinical Results. Gregg W. Stone, MD for the SPIRIT IV Investigators.

662 views • 36 slides

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

459 views • 31 slides

Robert A. Byrne, MB MRCPI

ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher and Endeavor Drug-Eluting Stents. Robert A. Byrne, MB MRCPI

467 views • 27 slides

Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton

Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI . Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton. Pathology. History (SVG trials). 30 Day MACE. Abciximab. Guardwire. Filterwire EX. Guardwire. Possible methods for embolic protection. Distal Protection UK 2003.

448 views • 25 slides

EXCITE ISR: Initial Results

EXCITE ISR: Initial Results. Eric J. Dippel, MD FACC On behalf of the EXCITE ISR Investigators. Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit. N/A

414 views • 22 slides

Bruno Scheller for the Paccocath ISR Study Group

TCT 2007 - Late Breaking Studies and First Report Investigations Wednesday, October 24 2007, Main area PACCOCATH ISR 1 and 2: A Prospective, Randomized Trial of a Paclitaxel-Eluting Balloon in In-Stent Restenosis: 2-Year Results. Bruno Scheller for the Paccocath ISR Study Group.

409 views • 16 slides

Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention

477 views • 11 slides

TAXUS II: Slow Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUS TM NIRx TM SR Stent

TAXUS II: Slow Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUS TM NIRx TM SR Stent. Presented at TCT 2002. TAXUS II: Study Overview. Randomized 1:1 Triple-blind 536 Patients TAXUS TM NIRx TM SR (n=267) TAXUS TM NIRx TM MR (n=269)

363 views • 10 slides